Loading...
Bilateral Trade Intelligence · $35.8K Total Trade · 1 Foreign Suppliers · 2 Indian Buyers · DGFT Verified · Updated March 2026
India imported $35.8K worth of pharmaceutical formulations from Vietnam, Democratic Rep across 2 verified shipments, from 1 foreign suppliers to 2 Indian buyers. The top suppliers are UNI- PRESIDENT VIETNAM CO., LTD ($35.8K). The leading products are Probiotics ($36K). Average shipment value: $17.9K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Probiotics | $35.8K | 100.0% |
India imports 1+ pharmaceutical formulations from Vietnam, Democratic Rep with a combined trade value of $35.8K. Key products include Probiotics ($36K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Vietnam, Democratic Rep, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Vietnam, Democratic Rep buyers, regulatory requirements, and logistics for that specific product corridor. Products include Probiotics ($36K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Vietnam, Democratic Rep. Leading exporters include Uni- President Vietnam Co., Ltd, . The top exporter accounts for 100.0% of total India–Vietnam, Democratic Rep pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between the Democratic People's Republic of Korea (North Korea) and India has been minimal, with only two shipments valued at $36,000 USD between 2022 and 2026. This limited trade suggests a nascent relationship, potentially due to geopolitical factors, regulatory challenges, and logistical constraints. The absence of significant trade volumes indicates that both nations have yet to establish a robust pharmaceutical trade partnership.
Vietnam's Democratic Republic has played a negligible role in India's pharmaceutical imports, with a total import value of $36,000 USD over two shipments from 2022 to 2026. The sole product imported during this period was probiotics, indicating a very limited engagement in India's pharmaceutical market. This minimal trade underscores the need for enhanced bilateral relations and trade facilitation to expand the scope of pharmaceutical imports from Vietnam's Democratic Republic to India.
Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) or new trade agreements affecting pharmaceutical imports from Vietnam's Democratic Republic. The lack of substantial developments during this period highlights the stagnant nature of the pharmaceutical trade corridor between the two nations. This stagnation suggests a pressing need for strategic initiatives to stimulate and diversify pharmaceutical trade between India and Vietnam's Democratic Republic.
2 companies in Vietnam, Democratic Rep import pharmaceutical formulations from India. Top buyers include Upin Trading Corporation, Pv Enterprises, . The largest buyer accounts for 57.5% of India–Vietnam, Democratic Rep pharma imports. Source: Indian Customs (DGFT).
Registration process, GMP requirements, import documentation
For pharmaceutical products to be imported into India, the Central Drugs Standard Control Organisation (CDSCO) mandates a comprehensive registration process. This process involves submitting an application form along with essential documents such as the Free Sale Certificate, Certificate of Pharmaceutical Product (CPP), and a site master file detailing the manufacturing facility's compliance with Good Manufacturing Practices (GMP). The evaluation process includes document verification and, if necessary, an inspection of the manufacturing site to ensure adherence to Indian safety and quality standards. The timeline for approval can vary, often taking several months, depending on the completeness of the application and the need for additional information or inspections.
India requires that manufacturing facilities in Vietnam's Democratic Republic adhere to Good Manufacturing Practices (GMP) as outlined by the World Health Organization (WHO). This includes compliance with quality assurance procedures and controls to ensure the safety and efficacy of pharmaceutical products. The CDSCO may conduct inspections to verify GMP compliance, and products must be accompanied by a Certificate of Pharmaceutical Product (CPP) issued by the National Regulatory Authority of the country of origin.
Importers must obtain an import license (Form 10) from the CDSCO, which requires submission of a registration certificate, No Objection Certificate (NOC), and a test license. The application process involves providing detailed product information, manufacturing licenses, and compliance with Indian safety and quality standards. Customs procedures include clearance of goods through designated ports, with adherence to cold chain logistics and Good Distribution Practices (GDP) to maintain product integrity.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Vietnam's Democratic Republic to India have been limited, with probiotics being the only product imported during the 2022-2026 period. This singular product category indicates a lack of diversity in the types of pharmaceutical products traded between the two nations. The absence of other therapeutic areas or product types suggests potential barriers to expanding the range of pharmaceutical imports from Vietnam's Democratic Republic to India.
Given the minimal pharmaceutical trade between Vietnam's Democratic Republic and India, there is a lack of imported innovator drugs, novel formulations, or advanced therapies from Vietnam's Democratic Republic that are not manufactured domestically in India. This limited trade underscores the need for strategic initiatives to diversify and enhance the pharmaceutical product offerings between the two countries.
The negligible pharmaceutical imports from Vietnam's Democratic Republic to India may be attributed to factors such as limited patent protection, technology gaps, and stringent quality requirements. The minimal trade volume suggests that these factors have hindered the establishment of a robust pharmaceutical trade relationship. Addressing these challenges is crucial to stimulate demand and foster a more dynamic pharmaceutical trade corridor between the two nations.
Tariff structure, trade agreements, IP and patent landscape
India's Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess on pharmaceutical formulations imported from Vietnam's Democratic Republic are subject to the prevailing trade policies and agreements. Specific rates can vary and are determined by the Directorate General of Foreign Trade (DGFT) and the Ministry of Finance. Importers should consult the latest notifications and guidelines from these authorities to determine applicable duties and taxes for pharmaceutical imports.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Vietnam's Democratic Republic concerning pharmaceutical imports. The absence of such agreements may contribute to the limited trade volume in this sector. Engaging in bilateral negotiations or exploring regional trade agreements could be potential avenues to enhance pharmaceutical trade between the two nations.
India's patent regime, including provisions under Section 3(d) of the Indian Patents Act, compulsory licensing, and price controls by the National Pharmaceutical Pricing Authority (NPPA), may impact the importation of pharmaceutical products. These regulations aim to balance the interests of patent holders and public health considerations, potentially influencing the attractiveness of importing certain pharmaceutical products from Vietnam's Democratic Republic.
Shipping routes, port infrastructure, cold chain compliance
The pharmaceutical trade between Vietnam's Democratic Republic and India is minimal, with only two shipments valued at $36,000 USD between 2022 and 2026. This limited trade suggests that established sea and air routes may not be optimized for pharmaceutical imports from Vietnam's Democratic Republic to India. Enhancing logistics infrastructure and establishing dedicated routes could facilitate more efficient and reliable trade between the two nations.
The minimal pharmaceutical trade between Vietnam's Democratic Republic and India indicates that key export ports in Vietnam's Democratic Republic and import ports in India may not be equipped with specialized facilities for handling pharmaceutical shipments. Upgrading port infrastructure to meet international standards for pharmaceutical imports could improve the efficiency and safety of trade between the two countries.
The limited pharmaceutical imports from Vietnam's Democratic Republic to India suggest that customs clearance procedures and cold chain logistics may not be well-established for such imports. Implementing streamlined customs procedures and robust cold chain management systems are essential to ensure the integrity and quality of pharmaceutical products during transit. Adhering to Good Distribution Practices (GDP) is crucial to maintain product efficacy and safety.
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports certain pharmaceutical products to meet domestic demand, especially in areas where domestic production is limited or non-existent. The minimal imports from Vietnam's Democratic Republic suggest that there may be opportunities to diversify sources and enhance the availability of specific pharmaceutical products in the Indian market.
The limited pharmaceutical trade between Vietnam's Democratic Republic and India indicates that there are currently no major pharmaceutical companies from Vietnam's Democratic Republic supplying products to India. Establishing local partnerships or engaging in contract manufacturing could be potential strategies for Vietnamese companies to enter the Indian pharmaceutical market.
India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce import dependency. While these policies may lead to a decrease in imports of certain pharmaceutical products, they also present opportunities for foreign companies, including those from Vietnam's Democratic Republic, to collaborate with Indian manufacturers and supply products that complement domestic production capabilities.
Competing origins, India's edge, challenges and threats
India imports pharmaceutical products from various countries, including the USA, EU, China, Switzerland, and Japan. The minimal imports from Vietnam's Democratic Republic suggest that these countries currently hold a larger share of the Indian pharmaceutical import market. Vietnam's Democratic Republic faces competition in terms of product diversity, quality standards, and established trade relationships.
Vietnam's Democratic Republic may offer competitive advantages such as cost-effective manufacturing, unique product formulations, or niche therapeutic areas. However, the limited trade volume indicates that these advantages have yet to be fully realized in the Indian market. Enhancing product quality, ensuring compliance with international standards, and establishing strong distribution networks are essential steps for Vietnamese companies to improve their competitiveness in India.
Indian pharmaceutical manufacturers are continually developing alternatives, including biosimilars, process patents, and expanding capacity under the PLI scheme. This domestic innovation and growth present challenges for foreign suppliers, including those from Vietnam's Democratic Republic, to establish a foothold in the Indian market. Collaborative efforts, such as joint ventures or contract manufacturing
India exported pharmaceuticals worth $35.8K to Vietnam, Democratic Rep across 2 verified shipments.
1. UNI- PRESIDENT VIETNAM CO., LTD — $35.8K. Total: 1 suppliers.
1. UPIN TRADING CORPORATION — $20.6K. 2. PV ENTERPRISES — $15.2K. 2 buyers total.
1. Probiotics ($35.8K, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $35.8K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$17.9K per consignment across 2 shipments.
1 Indian companies. Largest: UNI- PRESIDENT VIETNAM CO., LTD with $35.8K.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 2 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists